Vistagen Therapeutics, Inc. (VTGN) Eyes Breakthrough with Phase 3 Social Anxiety Trial
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is a late clinical-stage biopharmaceutical company developing neuroscience-focused therapies, including innovative intranasal pherine compounds.